Lexaria Bioscience (LEXX) has released an update.
Lexaria Bioscience has successfully completed the second stage of its innovative GLP-1 human pilot study, focusing on improving the delivery and effectiveness of diabetes medication semaglutide. The study compares a traditional swallowed tablet with two DehydraTECH-enhanced formulations, with final results expected after the upcoming third arm of the study. This groundbreaking research aims to overcome the absorption challenges of GLP-1 drugs in the stomach and show potential for fewer side effects and better drug delivery.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
